Earnings call transcript: Yunji Q2 2025 sees widened net loss amid revenue drop

Yunji Inc. reported a significant deterioration in its Q2 2025 financial performance, with total revenue declining 32% year-over-year to $158.3 million and net loss widening substantially to $100.7 million from $8 million in the prior year, amidst weakened consumer confidence. Despite a strong current ratio, the company is rapidly burning cash and is rated 'WEAK' by InvestingPro. In response, Yunji is focusing on aggressive cost optimization and gross margin improvement (currently 47.3%) to achieve breakeven, while strategically expanding its organic health product portfolio to navigate challenging market conditions.

Analysis

Yunji Inc. (YJ) reported a severe deterioration in its financial performance for the second quarter of 2025, reflecting significant operational and market-based challenges. Total revenue contracted by 32% year-over-year to $158.3 million, driven by weakened consumer confidence and a strategic refinement of its product offerings. More alarmingly, the net loss expanded dramatically to $100.7 million from an $8 million loss in the prior-year period. This was exacerbated by a substantial increase in General and Administrative expenses, primarily due to a high allowance for credit losses, which signals potential issues with receivables. Despite maintaining a relatively high gross margin of 47.3%, the company's operating expenses are unsustainable at the current revenue level. The company's liquidity is also under pressure; InvestingPro data indicates a rapid cash burn, with cash and equivalents declining to $217.1 million. In response, management is pursuing a high-stakes turnaround centered on an 'organic health strategy' and aggressive cost optimization with the goal of achieving breakeven. While new product launches show some nascent traction, their financial contribution is minimal compared to the overall revenue decline and mounting losses. The stock's low Price/Book ratio of 0.06 and a 'WEAK' financial health score of 1.35 out of 5 underscore the market's deep skepticism about the viability of this strategy.

Key Decisions for Investors

• Given the significant revenue decline, escalating net losses, and rapid cash burn, investors should treat Yunji as a high-risk special situation, where the low Price/Book ratio reflects distress rather than a clear value opportunity.
• The primary metric to monitor is the quarterly cash burn rate against the remaining $217.1 million in cash; failure to significantly slow this burn and show progress towards the stated goal of breakeven will increase liquidity risk.
• Investors should scrutinize the sales growth of the new organic health products, as the success of the company's entire turnaround strategy hinges on this pivot gaining substantial market traction to offset declines elsewhere.
• The sharp increase in the allowance for credit losses is a major red flag that warrants caution, suggesting investors should factor in heightened counterparty and operational risk.